Literature DB >> 23847057

Effect of antiretroviral therapy on HIV reservoirs in elite controllers.

Tae-Wook Chun1, J Shawn Justement, Danielle Murray, Connie J Kim, Jana Blazkova, Claire W Hallahan, Erika Benko, Cecilia T Costiniuk, Gabor Kandel, Mario Ostrowski, Rupert Kaul, Susan Moir, Joseph P Casazza, Richard A Koup, Colin Kovacs, Anthony S Fauci.   

Abstract

Elite controllers suppress human immunodeficiency virus (HIV) viremia to below the limit of detection in the absence of antiretroviral therapy (ART). However, precise frequencies of CD4(+) T cells carrying replication-competent HIV and/or the dynamics of the infectious viral reservoirs in response to initiation and discontinuation of ART in elite controllers are unknown. We show that the size of the pool of CD4(+) T cells harboring infectious HIV diminished significantly after initiation of ART and rebounded to baseline upon cessation of therapy. Our data provide compelling evidence that persistent viral replication occurs in untreated elite controllers even in the absence of detectable plasma viremia.

Entities:  

Keywords:  antiretroviral therapy; elite controllers; human immunodeficiency virus; viral reservoirs

Mesh:

Substances:

Year:  2013        PMID: 23847057      PMCID: PMC3789563          DOI: 10.1093/infdis/jit306

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

1.  HIV-1 continues to replicate and evolve in patients with natural control of HIV infection.

Authors:  Helene Mens; Mary Kearney; Ann Wiegand; Wei Shao; Kristian Schønning; Jan Gerstoft; Niels Obel; Frank Maldarelli; John W Mellors; Thomas Benfield; John M Coffin
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

2.  Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus.

Authors:  Karen A O'Connell; Timothy P Brennan; Justin R Bailey; Stuart C Ray; Robert F Siliciano; Joel N Blankson
Journal:  J Virol       Date:  2010-05-05       Impact factor: 5.103

3.  CD4 T cell count reconstitution in HIV controllers after highly active antiretroviral therapy.

Authors:  Jason F Okulicz; Greg A Grandits; Amy C Weintrob; Michael L Landrum; Anuradha Ganesan; Nancy F Crum-Cianflone; Brian K Agan; Vincent C Marconi
Journal:  Clin Infect Dis       Date:  2010-04-15       Impact factor: 9.079

4.  HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.

Authors:  Maria J Buzón; Marta Massanella; Josep M Llibre; Anna Esteve; Viktor Dahl; Maria C Puertas; Josep M Gatell; Pere Domingo; Roger Paredes; Mark Sharkey; Sarah Palmer; Mario Stevenson; Bonaventura Clotet; Julià Blanco; Javier Martinez-Picado
Journal:  Nat Med       Date:  2010-03-14       Impact factor: 53.440

Review 5.  Antiretroviral therapy and management of HIV infection.

Authors:  Paul A Volberding; Steven G Deeks
Journal:  Lancet       Date:  2010-07-03       Impact factor: 79.321

6.  Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy.

Authors:  Steven A Yukl; Amandeep K Shergill; Kenneth McQuaid; Sara Gianella; Harry Lampiris; C Bradley Hare; Mark Pandori; Elizabeth Sinclair; Huldrych F Günthard; Marek Fischer; Joseph K Wong; Diane V Havlir
Journal:  AIDS       Date:  2010-10-23       Impact factor: 4.177

7.  A comparison of viral loads between HIV-1-infected elite suppressors and individuals who receive suppressive highly active antiretroviral therapy.

Authors:  Jason B Dinoso; Scott Y Kim; Robert F Siliciano; Joel N Blankson
Journal:  Clin Infect Dis       Date:  2008-07-01       Impact factor: 9.079

8.  T cell dynamics and the response to HAART in a cohort of HIV-1-infected elite suppressors.

Authors:  Ahmad R Sedaghat; Darius A Rastegar; Karen A O'Connell; Jason B Dinoso; Claus O Wilke; Joel N Blankson
Journal:  Clin Infect Dis       Date:  2009-12-01       Impact factor: 9.079

9.  Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy.

Authors:  Hiroyu Hatano; Eric L Delwart; Philip J Norris; Tzong-Hae Lee; Joan Dunn-Williams; Peter W Hunt; Rebecca Hoh; Susan L Stramer; Jeffrey M Linnen; Joseph M McCune; Jeffrey N Martin; Michael P Busch; Steven G Deeks
Journal:  J Virol       Date:  2008-10-22       Impact factor: 5.103

10.  The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial.

Authors:  Rajesh T Gandhi; Lu Zheng; Ronald J Bosch; Ellen S Chan; David M Margolis; Sarah Read; Beatrice Kallungal; Sarah Palmer; Kathy Medvik; Michael M Lederman; Nadia Alatrakchi; Jeffrey M Jacobson; Ann Wiegand; Mary Kearney; John M Coffin; John W Mellors; Joseph J Eron
Journal:  PLoS Med       Date:  2010-08-10       Impact factor: 11.069

View more
  35 in total

1.  Antiretroviral therapy in HIV-infected elite controllers: impact on gut immunology, microbial translocation, and biomarkers of serious non-AIDS conditions.

Authors:  Connie J Kim; Colin Kovacs; Tae-Wook Chun; Gabor Kandel; Brendan J W Osborne; Sanja Huibner; Kamnoosh Shahabi; Feng-Yun Yue; Erika Benko; Mario Ostowski; Rupert Kaul
Journal:  J Acquir Immune Defic Syndr       Date:  2014-12-15       Impact factor: 3.731

Review 2.  Post-Treatment Controllers: Role in HIV "Cure" Research.

Authors:  Leslie R Cockerham; Hiroyu Hatano; Steven G Deeks
Journal:  Curr HIV/AIDS Rep       Date:  2016-02       Impact factor: 5.071

3.  HLA-B*57 elite suppressor and chronic progressor HIV-1 isolates replicate vigorously and cause CD4+ T cell depletion in humanized BLT mice.

Authors:  Maria Salgado; Michael D Swanson; Christopher W Pohlmeyer; Robert W Buckheit; Jin Wu; Nancie M Archin; Thomas M Williams; David M Margolis; Robert F Siliciano; J Victor Garcia; Joel N Blankson
Journal:  J Virol       Date:  2014-01-03       Impact factor: 5.103

4.  HIV reservoirs as obstacles and opportunities for an HIV cure.

Authors:  Tae-Wook Chun; Susan Moir; Anthony S Fauci
Journal:  Nat Immunol       Date:  2015-06       Impact factor: 25.606

5.  AIDS virus seeks refuge in B cell follicles.

Authors:  Hendrik Streeck
Journal:  Nat Med       Date:  2015-02       Impact factor: 53.440

6.  Human Immunodeficiency Virus (HIV).

Authors: 
Journal:  Transfus Med Hemother       Date:  2016-05-09       Impact factor: 3.747

7.  Control issues.

Authors:  Alla Katsnelson
Journal:  Nat Med       Date:  2014-04       Impact factor: 53.440

8.  Multiple Origins of Virus Persistence during Natural Control of HIV Infection.

Authors:  Eli A Boritz; Samuel Darko; Luke Swaszek; Gideon Wolf; David Wells; Xiaolin Wu; Amy R Henry; Farida Laboune; Jianfei Hu; David Ambrozak; Marybeth S Hughes; Rebecca Hoh; Joseph P Casazza; Alexander Vostal; Daniel Bunis; Krystelle Nganou-Makamdop; James S Lee; Stephen A Migueles; Richard A Koup; Mark Connors; Susan Moir; Timothy Schacker; Frank Maldarelli; Stephen H Hughes; Steven G Deeks; Daniel C Douek
Journal:  Cell       Date:  2016-07-21       Impact factor: 41.582

9.  Maintenance of HIV-Specific Memory B-Cell Responses in Elite Controllers Despite Low Viral Burdens.

Authors:  Clarisa M Buckner; Lela Kardava; Xiaozhen Zhang; Kathleen Gittens; J Shawn Justement; Colin Kovacs; Adrian B McDermott; Yuxing Li; Mohammad M Sajadi; Tae-Wook Chun; Anthony S Fauci; Susan Moir
Journal:  J Infect Dis       Date:  2016-04-27       Impact factor: 5.226

10.  Long-Term Spontaneous Control of HIV-1 Is Related to Low Frequency of Infected Cells and Inefficient Viral Reactivation.

Authors:  Nicolas Noel; Ruth Peña; Annie David; Veronique Avettand-Fenoel; Itziar Erkizia; Esther Jimenez; Camille Lecuroux; Christine Rouzioux; Faroudy Boufassa; Gianfranco Pancino; Alain Venet; Carine Van Lint; Javier Martinez-Picado; Olivier Lambotte; Asier Sáez-Cirión; Julia G Prado
Journal:  J Virol       Date:  2016-06-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.